About: Almorexant

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Almorexant, also known by its development code ACT-078573, is an orexin antagonist, acting as a competitive antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011 due to concerns over the hepatic safety of almorexant after transient increases in liver enzymes were observed in trials.

Property	Value
dbo:abstract	Almorexant, also known by its development code ACT-078573, is an orexin antagonist, acting as a competitive antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011 due to concerns over the hepatic safety of almorexant after transient increases in liver enzymes were observed in trials. (en)
dbo:casNumber	871224-64-5 913358-93-7 (HCl)
dbo:chEMBL	455136
dbo:class	dbr:Orexin_antagonist
dbo:fdaUniiCode	9KCW39P2EI
dbo:kegg	D09964
dbo:pubchem	23727689
dbo:thumbnail	wiki-commons:Special:FilePath/Almorexant.svg?width=300
dbo:wikiPageExternalLink	https://web.archive.org/web/20080514235534/http:/www.actelion.com/
dbo:wikiPageID	19451365 (xsd:integer)
dbo:wikiPageLength	7577 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1113743340 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Calcium dbr:Benzodiazepine dbr:Blockbuster_drug dbc:Abandoned_drugs dbc:Acetamides dbc:Sedatives dbc:Trifluoromethyl_compounds dbr:Oral_administration dbr:Orexin_antagonist dbr:GlaxoSmithKline dbr:Liver dbr:Clinical_trial dbr:Receptor_antagonist dbr:Actelion dbr:Drug_development dbr:Generic_term dbr:Hydrochloride dbr:Orexin_receptor dbc:Orexin_antagonists dbc:Norsalsolinol_ethers dbr:Insomnia dbr:Z-drug dbr:Duration_of_action
dbp:atcPrefix	None (en)
dbp:c	29 (xsd:integer)
dbp:casNumber	871224 (xsd:integer)
dbp:casSupplemental	913358 (xsd:integer)
dbp:chembl	455136 (xsd:integer)
dbp:chemspiderid	21377865 (xsd:integer)
dbp:class	dbr:Orexin_antagonist
dbp:eliminationHalfLife	13 (xsd:integer)
dbp:f	3 (xsd:integer)
dbp:h	31 (xsd:integer)
dbp:iupacName	-2 (xsd:integer)
dbp:iupharLigand	2886 (xsd:integer)
dbp:kegg	D09964 (en)
dbp:metabolism	dbr:Liver
dbp:n	2 (xsd:integer)
dbp:o	3 (xsd:integer)
dbp:pubchem	23727689 (xsd:integer)
dbp:routesOfAdministration	dbr:Oral_administration
dbp:smiles	CNC[C@@H]N2CCC3=CCOC (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	DKMACHNQISHMDN-RPLLCQBOSA-N (en)
dbp:synonyms	ACT-078573 (en)
dbp:unii	9 (xsd:integer)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	477318417 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:width	200 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Abbrlink dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Orexin_receptor_modulators
dct:subject	dbc:Abandoned_drugs dbc:Acetamides dbc:Sedatives dbc:Trifluoromethyl_compounds dbc:Orexin_antagonists dbc:Norsalsolinol_ethers
gold:hypernym	dbr:Antagonist
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Abstraction100002137 yago:Acetamide114711197 yago:Amide114724264 yago:Chemical114806838 yago:Compound114818238 yago:Element114840755 yago:Material114580897 yago:Matter100020827 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Quintessence114847103 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:WikicatAcetamides yago:WikicatPhenolEthers umbel-rc:DrugProduct
rdfs:comment	Almorexant, also known by its development code ACT-078573, is an orexin antagonist, acting as a competitive antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011 due to concerns over the hepatic safety of almorexant after transient increases in liver enzymes were observed in trials. (en)
rdfs:label	Almorexant (en)
owl:sameAs	freebase:Almorexant yago-res:Almorexant wikidata:Almorexant dbpedia-fi:Almorexant dbpedia-sh:Almorexant dbpedia-sr:Almorexant dbpedia-vi:Almorexant https://global.dbpedia.org/id/431We
prov:wasDerivedFrom	wikipedia-en:Almorexant?oldid=1113743340&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Almorexant.svg
foaf:homepage	https://web.archive.org/web/20080514235534/http:/www.actelion.com/
foaf:isPrimaryTopicOf	wikipedia-en:Almorexant
is dbo:wikiPageRedirects of	dbr:C29H32ClF3N2O3 dbr:C29H31F3N2O3 dbr:Almorexant_hydrochloride dbr:ACT-078573
is dbo:wikiPageWikiLink of	dbr:C29H32ClF3N2O3 dbr:SB-649868 dbr:Orexin_antagonist dbr:C29H31F3N2O3 dbr:Eszopiclone dbr:Hypocretin_(orexin)_receptor_1 dbr:Hypocretin_(orexin)_receptor_2 dbr:Orexin_receptor dbr:Suvorexant dbr:Metofoline dbr:List_of_signaling_peptide/protein_receptor_modulators dbr:TCS-OX2-29 dbr:List_of_drugs:_Al dbr:Almorexant_hydrochloride dbr:ACT-078573
is foaf:primaryTopic of	wikipedia-en:Almorexant